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Abstract
Immersion pulmonary edema (IPE) is a misdiagnosed environmental illness caused by water immersion, cold, and exertion. IPE
occurs typically during SCUBA diving, snorkeling, and swimming. IPE is sometimes associated with myocardial injury and/or loss of
consciousness in water, which may be fatal. IPE is thought to involve hemodynamic and cardiovascular disturbances, but its
pathophysiology remains largely unclear, which makes IPE prevention difﬁcult. This observational study aimed to document IPE
pathogenesis and improve diagnostic reliability, including distinguishing in some conditions IPE from decompression sickness (DCS),
another diving-related disorder.
Thirty-one patients (19 IPE, 12 DCS) treated at the Hyperbaric Medicine Department (Ste-Anne hospital, Toulon, France; July
2013–June 2014) were recruited into the study. Ten healthy divers were recruited as controls. We tested: (i) copeptin, a surrogate
marker for antidiuretic hormone and a stress marker; (ii) ischemia-modiﬁed albumin, an ischemia/hypoxia marker; (iii) brain-natriuretic
peptide (BNP), a marker of heart failure, and (iv) ultrasensitive-cardiac troponin-I (cTnI), a marker of myocardial ischemia.
We found that copeptin and cardiac biomarkers were higher in IPE versus DCS and controls: (i) copeptin: 68%of IPE patients had a
high level versus 25% of DCS patients (P<0.05) (mean±standard-deviation: IPE: 53±61pmol/L; DCS: 15±17; controls: 6±3; IPE
versus DCS or controls: P<0.05); (ii) ischemia-modiﬁed albumin: 68% of IPE patients had a high level versus 16% of DCS patients
(P<0.05) (IPE: 123±25 arbitrary-units; DCS: 84±25; controls: 94±7; IPE versus DCS or controls: P<0.05); (iii) BNP: 53% of IPE
patients had a high level, DCS patients having normal values (P<0.05) (IPE: 383±394ng/L; DCS: 37±28; controls: 19±15; IPE
versus DCS or controls: P<0.01); (iv) cTnI: 63% of IPE patients had a high level, DCS patients having normal values (P<0.05) (IPE:
0.66±1.50mg/L; DCS: 0.0061±0.0040; controls: 0.0090±0.01; IPE versus DCS or controls: P<0.01). The combined “BNP-cTnI”
levels providedmost discrimination: all IPE patients, but none of the DCS patients, had elevated levels of either/both of thesemarkers.
We propose that antidiuretic hormone acts together with a myocardial ischemic process to promote IPE. Thus, monitoring of
antidiuretic hormone and cardiac biomarkers can help to make a quick and reliable diagnosis of IPE.
Abbreviations:ADH = antidiuretic hormone, AU= arbitrary units, BNP = brain natriuretic peptide, CRP =C-reactive protein, DCS
= decompression sickness, H+6 = 6 hours after admission to the hospital, H0 = time of emergency admission to the hospital, IMA =
ischemia-modiﬁed albumin, IPE = immersion pulmonary edema, us cTnI = ultrasensitive cardiac troponin I.
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1. Introduction distinguish IPE from DCS in some challenging conditions by
Louge et al. Medicine (2016) 95:26 MedicineImmersion pulmonary edema (IPE) is a serious environmental
illness caused by water immersion, cold, and exertion, and occurs
during popular water sports such as SCUBA diving, snorkeling,
and swimming. Cases are also reported among professional
divers, military swimmers, and triathletes.[1–4] IPE pathophysiol-
ogy is unclear and its incidence is difﬁcult to determine accurately
because many cases are thought to be misdiagnosed. IPE is
characterized by dyspnea, cough, haemoptysis, hypoxemia, and
extreme fatigue.[1–4]Most patients recover from IPEwith rest and
oxygen and/or betamimetic therapy, but IPE is sometimes
associated with myocardial injury and/or loss of consciousness,
which may have a fatal outcome in a water environment.[4–9] The
fragmented knowledge of IPE pathophysiology is a hurdle to
deducing new approaches to prevent the disorder and identifying
patients with IPE as soon as possible in a context where
established biochemical markers are not available.
First, the pathogenesis of IPE is thought to imply hemodynamic
and cardiorespiratory disorders that induce leakage of ﬂuid out of
the lumen of the capillary into the interstitial space, and
eventually into the alveolar airspace.[1–4] Various events are
involved in ﬂuid leakage including (i) increased capillary pressure
resulting from increased cardiac preload following blood
redistribution from peripheral to thoracic vessels induced by
exertion in immersion conditions, and afterload following
vasoconstriction induced by cold and/or emotional stress,[2,10,11]
(ii) decreased alveolar pressure resulting from ventilatory
constraints when breathing dense gas, and (iii) changes in lung
capillaries’ permeability.[2–4] These elements are consistent with
the clinical manifestations described above[1–4] and suggest that
acute heart failure occurs during IPE. They also suggest that an
investigation in IPE patients of cardiac biomarkers such as the
brain natriuretic peptide (BNP, a marker of heart failure) and
troponin (a marker of myocardial ischemia) might be informative
to support an unambiguous diagnosis.
Second, the pathogenesis of IPE is often associated with
hypoxemia,[1,2,12] suggesting a hypoxic/ischemic component to
the illness, which could be monitored by ischemia-modiﬁed
albumin (IMA), a marker produced by hypoxemic/ischemic
tissues when O2 supply does not meet tissue demands following
limited O2 supply or excessive O2 demand.
[13]
Third, the pathogenesis of IPE implies environmental
(e.g., pressure and cold) and emotional stressors that induce
hemodynamic and volemic changes via the release of various
effectors, notably the antidiuretic hormone vasopressin
(ADH).[1,2,10,11,14,15] Because ADH controls volemia and affects
the cardiovascular system,[14,15] it may be a key player in IPE
and its measure via a surrogate marker, copeptin, the stable
C-terminal domain of the hormone precursor,[16–19] is feasible.
Additionally, copeptin is a nonspeciﬁc but early marker of severe
stress reactions,[16,17] and its release has been described in acute
coronary syndrome,[18] congestive heart failure, and lung injury.[19]
In this prospective study, the situation with regard to these
markers in IPE was compared with that observed in decompres-
sion sickness (DCS), another diving-related disorder that is
caused by the formation of gas bubbles in tissues.[20] DCS
symptoms include mechanical and embolic manifestations.[20]
The initial diagnosis of IPE and DCS is on their typical clinical
presentation, but the distinction between them is sometimes
difﬁcult in an emergency situation, at an early stage or in
some environmental conditions (e.g., long/deep diving, cold
water).[1,2,10,20,21,22] We, therefore, also sought to help2characterizing the biomarkers outlined above in each disorder.
In summary, the present observational study was aimed at
understanding the pathophysiology of IPE by evaluating cardiac
function, kidney function, and hypoxia biomarkers, and to
review the resulting data to improve the reliability of IPE
diagnosis, particularly to distinguish IPE from DCS.
2. Methods
2.1. SCUBA divers’ inclusion
In this prospective approach, all the 31 patients (19 IPE, 12 DCS)
treated at the Emergency Unit of the Department of Hyperbaric
Medicine (Sainte-Anne Hospital, Toulon, France) between July
2013 and June 2014 were consecutively included. None of the
patients refused to participate, and none were excluded. Ten
healthy divers were recruited as controls for biochemical analysis,
and blood samples were collected after SCUBA diving. The Ethics
Committee at the university hospital gave its agreement,
informed consents were obtained before inclusion, and the
protocol followed the guidelines of the 1975 Declaration of
Helsinki. Blood pressure measurement and venous blood
sampling (5mL of whole blood on sodium heparinate, or on
sodium EDTA for the BNP assay) were performed on hospital
admission for all groups. Blood gas analysis was performed on
admission for IPE patients only (2mL of arterial blood). An
additional biochemical check-up was performed 6hours later for
the IPE group, sufﬁcient time to enable signiﬁcant changes to
occur in the biomarkers monitored. Circulating bubble detection
was performed by pulsed Doppler echocardiography for all
symptomatic divers. IPE diagnosis was based on interstitial
inﬁltrates on chest computed tomography scan (n=10), or on
lung comets by chest sonography (n=9). DCS diagnosis was
based on paraesthesia with sensitive/motor defect.
2.2. Copeptin measurement
Copeptin was measured using the BRAHMS Copeptin US
KRYPTOR assay (Thermo Fischer) (detection threshold: 1pmol/
L; inter- or intra-assay variation: <10%; normal value: <13
pmol/L).[23]
2.3. Albumin and IMA measurement
Albumin was measured on a COBAS 8000 apparatus (Roche,
Switzerland). IMA was measured using the Albumin Cobalt
Binding test, a quantitative in vitro diagnostic assay (Ischemia
Technologies, Denver, CO) that detects IMA by measuring the
cobalt-binding capacity of albumin in serum using a Synchron
LX20 analyzer (Beckman Coulter, France) (expressed in
arbitrary units, AU; detection threshold: 10 AU; intra-assay
variation: <5%; normal value: <100 AU).[24]
2.4. Measurement of cardiac troponin-I (cTnI)
cTnI was measured on an ADVIA Centaur apparatus (Siemens,
Germany) using an immunochemical method (range: 0.005–50m
g/L; intra-assay variation: <10%; normal value: <0.05mg/L).
2.5. BNP measurement
BNP was measured on an ADVIA Centaur apparatus using a
2-site sandwich immunoassay (range: 2–2000ng/L; intra-assay
variation: 10%; normal value: <100ng/L).
2.6. C-reactive protein (CRP) measurement diver with “chokes” or both IPE and DCS was included. All IPE
Louge et al. Medicine (2016) 95:26 www.md-journal.comThe Ultra-Sensitive CRP (US-CRP) marker was measured using a
COBAS 8000 apparatus (detection threshold: 0.05mg/L; intra-
assay variation: <10%; normal: <5mg/L).2.7. Statistical analysis
3.2. Natremia, albuminemia, CRPQuantitative variables were expressed as means± standard
deviation (SD) or medians and interquartile range (IQR). The
ANOVA 2-way analysis was used for intergroup comparisons
and the Wilcoxon test for intraindividual comparisons. For age,
sex, and dive parameters between groups, t test of Fischer-test
was used. Statistical tests were 2-sided and P<0.05 was
considered signiﬁcant. Analyses were performed using R-
Software (Project for Statistical Computing; v.2.8.1). The
sensitivity and speciﬁcity of each biomarker were calculated
for predicting IPE.3. Results
3.3. Copeptin3.1. Characteristics of the subjects
Clinical characteristics of the subjects are given in Table 1.
Among the 31 patients, we recruited, 19 were diagnosed with IPE
and 12 with DCS. The patient groups did not differ signiﬁcantly
in age, gender, dive duration, or dive depth (Table 1). Circulating
bubbles were not detected in IPE patients, which suggests that noTable 1
Diving parameters and clinical characteristics.
Characteristics Immersion pulmonary edema n=19
Age (y) 50 (24–74)
Gender (M/F) 14/5
Diving duration (min) 34 (15–90)
Depth (m) 30 (3–59)
Breathing gas Air
Clinical manifestations Anxiety n=18
Dyspnea n=18
Cough n=11
Hemoptysia n=9
Blood-tinged sputum
expectoration n=7
Cyanosis n=2
Fainting n=1
Systolic blood pressure 153 (95–190)
∗
Diastolic blood pressure 81 (57–115)
(mm Hg)
Albumin (g/L) 34 (31–37)
Natremia (mmol/L) 131 (129–137)
∗
C-react. prot. (mg/L) 3.6 (0.3–26)
pO2 (Pa) (art. blood) 9199 (4399–17,331)
Sat (%) 94 (83–100)
pH 7.40 (7.34–7.48)
Lactates (mmol/L) 1.7 (0.6–4.5)
Medical history Hypertension n=3
Dyslipidemia n=3
Smoker n=2
Coronary artery disease n=1
Migrainous n=1
Data were expressed as median (range). Biological data were compared using ANOVA 2-way analysis. For
Software (Project for Statistical Computing; v.2.8.1) was used.
∗
P<0.05 compared with decompression sickness or control subjects.
3patients were treated with oxygen for 2hours and 8 with
betamimetics and/or aerosol. Systolic blood pressure was higher
in IPE patients versus DCS and controls. It is of note that in DCS
patients, Cutis Marmorata was observed in 1 patient and
vestibular disorder was diagnosed in another patient (presence of
vertigo). DCS patients were treated with oxygen (2.8 ATA for 3±
1hours). There were no procedural errors (e.g., missing
decompression, emergency ascent). The mean time for admission
of patients, between symptoms and emergency admission, was
90±15minutes. No sequelae were observed among the patients
of either group.At the time of admission to the emergency unit (H0), mean
albuminemia did not signiﬁcantly differ between IPE, DCS, and
controls although the mean concentration tended to be lower in
the IPE group than in the 2 other groups (Table 1). Mean
natremia was slightly lower in the IPE group than in the 2 other
groups. The mean CRP level tended to be higher in the IPE group
than in the 2 other groups.At H0, the level was higher in the IPE group than in the DCS
group and in the controls (Data expressed as mean±SD: 53±61,Decompression sickness n=12 Controls n=10
51 (32–66) 45 (28–56)
10/2 7/3
41 (21–63) 35 (20–45)
38 (25–55) 39 (20–50)
Air Air
Medullar injuries: n=10
Paraparesia n=5
Tetraparesia n=1
Paraesthesia n=6
Dysesthesia n=7
Cutaneous injuries
n=1
Stroke n=1
(Hemiparesia)
Inner ear n=1
(Vertigo)
140 (125–180) 136 (110–135)
80 (69–110) 70 (68–85)
36 (29–37) 38 (30–40)
138 (135–140) 141 (140–145)
1.15 (0.3–4.5) 1.3 (0.3–3)
Not performed Not performed
Hypertension n=1
Dyslipidemia n=1
Smoker n=1
Coronary artery disease n=1
age, sex, and diving parameters, t test of Fischer-test was used. Statistical tests were 2-sided. The R-
15±17, and 6±3pmol/L, respectively; IPE versus DCS or 3.5. BNP
Figure 1. Copeptin. Copeptin (pmol/L), a surrogate marker for the antidiuretic
hormone and a stress marker, was evaluated in patients with immersion
pulmonary edema (IPE; n=19) or decompression sickness (DCS; n=12), and
in healthy divers (Controls; n=10). Biological parameters were evaluated on
admission to the emergency unit (H0) for all patients and 6hours later (H+6) for
IPE patients. Data are expressed as median, interquartile range, min, max.
DCS=decompression sickness, IPE= immersion pulmonary edema.
Figure 3. Ischemia-modiﬁed albumin. IMA (arbitrary units, AU), an ischemia/
hypoxia marker, was evaluated in patients with immersion pulmonary edema
(IPE; n=19) or decompression sickness (DCS; n=12), and in healthy divers
(n=10; controls) (AU: arbitrary units). Biological parameters were evaluated on
admission to the emergency unit (H0) for all patients, and 6hours later (H+6) for
IPE patients. Data are expressed as median, interquartile range, min, max.
AU=arbitrary units, IMA, DCS=decompression sickness, IMA= ischemia-
modiﬁed albumin, IPE= immersion pulmonary edema.
Louge et al. Medicine (2016) 95:26 Medicinecontrols: P<0.05) (data are also expressed as median and
interquartiles (IQRs) and presented in the ﬁgures thereafter, e.g.,
Fig. 1 for the copeptin level). Among the IPE patients, 68% (13/
19) had an abnormal level (>13pmol/L) compared with 25% (3/
12) of DCS patients (P<0.05; Fig. 2). Six hours after admission
(H+6), the level decreased in IPE (19±21pmol/L), but it
remained higher than in DCS (Fig. 1). No signiﬁcant difference
was found between the DCS patients and the controls.
3.4. IMA
At H0, the level was higher in the IPE group than in the DCS
group and in the controls (mean±SD: 123±25, 84±25, and 94
±7 AU, respectively; IPE versus DCS or controls: P<0.05;
median and IQRs are given in Fig. 3). Among the IPE patients,
68% (13/19) had an abnormal level (>100 AU) compared with
16% (2/12) of DCS patients (P<0.05; Fig. 2). At H+6, the level
decreased in IPE (105±9 AU), but it remained higher than in
DCS (Fig. 3). No signiﬁcant difference was found between the
DCS patients and the controls.Figure 2. Marker levels in the patients’ population. Percentage of patients’
population with level above a given threshold value on admission to
the emergency unit is given (Copeptin: >13pmol/L; IMA: >100 AU; BNP:
>100ng/L; cTnI: >0.05mg/L).
4At H0, the level was higher in the IPE group than in the DCS
group and in the controls (mean±SD: 383±394, 37±28, and 19
±15ng/L, respectively; IPE versus DCS or controls: P<0.01;
median and IQRs are given in Fig. 4). Although 53% (10/19) of
IPE patients had an abnormal level (>100ng/L), none of the DCS
patients had an abnormal level (P<0.05; Fig. 2). At H+6, the
level decreased in IPE (132±105ng/L), but it remained higher
than in DCS (Fig. 4). No signiﬁcant difference was found between
the DCS patients and the controls.
3.6. cTnI
AtH0, the level was higher in the IPE group than in theDCS group
and in the controls (mean±SD: 0.66±1.50, 0.0061±0.004, and
0.009±0.01mg/L, respectively; IPE versus DCS or controls: P<
0.01; median and IQRs are given in Fig. 5). Although 63% (12/19)
of IPE patients had an abnormal level (>0.05mg/L), none of the
DCS patients had an abnormal level (P<0.05; Fig. 2). AtH+6, the
level increased in IPE (1.3±2.4mg/L) versus the level measured atFigure 4. Brain natriuretic peptide. BNP (ng/L), a marker of heart failure, was
evaluated in patients with immersion pulmonary edema (IPE; n=19) or
decompression sickness (DCS; n=12), and in healthy divers (n=10). Biological
parameters were evaluated on admission to the emergency unit (H0) for all
patients, and 6hours later (H+6) for IPE patients. Data are expressed as
median, interquartile range, min, max.BNP, brain natriuretic peptide; DCS=
decompression sickness, IPE= immersion pulmonary edema.
H0 (Fig. 5). No signiﬁcant difference was found between the DCS
volemic status in IPE and DCS may explain why these disorders
Figure 5. Cardiac troponin I. Us-cTnI (mg/L), a marker of myocardial ischemia,
was evaluated in patients with immersion pulmonary edema (IPE; n=19) or
decompression sickness (DCS; n=12), and in healthy divers (n=10). Biological
parameters were evaluated on admission to the emergency unit (H0) for all
patients, and 6hours later (H+6) for IPE patients. Data are expressed as
median, interquartile range, min, max. DCS=decompression sickness, IPE=
immersion pulmonary edema.
Table 2
Sensitivity and speciﬁcity of cardiac markers in divers with
immersion pulmonary edema (n=19).
BNP cTnI IMA Copeptin
Sensitivity (%) 53 63 68 68
Speciﬁcity (%) 100 100 83 75
BNP=brain natriuretic peptide, cTnI= troponin I c, IMA= ischemia-modiﬁed albumin.
Louge et al. Medicine (2016) 95:26 www.md-journal.compatients and the controls.
Most importantly, when we examined BNP (see also x3.5 and
Fig. 4) and cTnI (see also x3.6 and Fig. 5) levels in each individual
patient, we found that all IPE patients had elevated levels of
either/both of these markers (Fig. 2 and Table 2), contrary to the
DCS patients who all had normal values.4. Discussion
Acknowledgments
ReferencesWe observed here that most IPE patients had higher levels of
copeptin, IMA, BNP and/or cTnI than DCS patients. Conversely,
we found no signiﬁcant difference between DCS patients and the
control subjects. The level of cTnI and/or BNP provided most
discrimination between IPE and DCS: all IPE patients, and none
of the DCS patients, had elevated levels of either/both of these
markers.
The ﬁrst major ﬁnding of this study is that a high copeptin level
is associated with IPE, which can be put in perspective with the
observation that copeptin is elevated in heart failure.[19,25] The
increase in the copeptin level, and hence in ADH production, in
IPE supports a role of ADH via its well-known capacity of
inhibiting diuresis and inducing renal vasoconstriction.[14,15]
More speciﬁcally, we propose that IPE occurs in a context of
decreased diuresis, which increases volemia and eventually blood
pressure. The situation observed in IPE contrasts with that
observed in healthy divers for whom water immersion is
associated with increased diuresis.[15]
That ADH promotes hypervolemia in IPE is consistent with 2
observations: (i) our ﬁndings that natremia and albuminemia
tended to be lower in IPE patients, and blood pressure higher
(Table 1); (ii) a previous report that predive hydration prevents
bubble formation within body tissues in DCS.[26] The contrasting5only rarely coexist.[21,22]
The second major observation of this study is that IPE involves
both heart failure processes and myocardial ischemia as shown
by the high BNP- and cTnI-level, respectively. BNP was reported
to increase during SCUBA diving and high BNP and troponin
levels were found also in previous IPE studies that did not
compare IPE to DCS patients.[7,10,11,27] We conﬁrmed here that
IPE patients typically had high BNP levels, which is consistent
with an increased ﬁlling pressure. Regarding ultrasensitive-cTnI,
our results can also be interpreted pathophysiologically: taking
into account the time necessary (i) for ultrasensitive-cTnI to rise
after myocardial ischemia (2–3hours),[28] (ii) the mean diving-
duration (34minutes; Table 1), and (iii) the mean time between
symptoms and hospital admission (90minutes), our data suggest
that IPE originates from amyocardial ischemia process beginning
early in the diving session, with decompensation and symptoms
occurring when the diver surfaces. This hypothesis is in
agreement with a recent report showing that triathletes
experience IPE quickly (within about 10minutes) after water
immersion.[4]
The third major point of our study is the high level of IMA in
IPE. This characteristic reﬂects an ischemia/hypoxia process as
IMA levels increase during experimental hypoxia,[29] but also
during acute coronary syndrome or chronic heart failure.[30,31]
As expected, the high level observed here in IPE patients
decreased after the oxygen treatment that reduced hypoxia (H+6;
Fig. 3).
Four main considerations necessarily limit this study: (i) we
included during 1 year all patients treated at the Hyperbaric
Department of an hospital that covers ∼30% of the French
Mediterranean shore, and it would be useful to increase the size
of the panel to improve the signiﬁcance of our ﬁndings; (ii) we did
not include divers with “chokes” or patients presenting both IPE
and DCS due to the very low incidence of such cases,[21,22] and it
would be interesting to study these patients for the same markers
if possible; (iii) we did not speciﬁcally address diuresis in the
subjects followed here, and this could be important to directly
address the effect of ADH in IPE; (iv) although we used
biochemical analysis apparatus in hospital conditions after
emergency admission, it would be interesting to compare our
results with those obtained using the new generation of portable
diagnostic equipment that can be installed on dive boats in order
to examine whether measurement of cTnI and BNP soon after the
dive has ﬁnished can help in the management of patients with
diving disorders.
We conclude that the increase in ADH and troponin-I levels
indicates that antidiuretic effects increasing blood pressure act in
the context of myocardial ischemia and promote IPE. Accord-
ingly, measuring cardiac biomarkers could be helpful for early
identiﬁcation of IPE or, in some conditions, to distinguish IPE
from DCS.The authors thank the technical staff of the Sainte-Anne hospital.[1] Pons M, Blickenstorfer D, Oechslin E, et al. Pulmonary oedema in
healthy persons during scuba-diving and swimming. Eur Resp J
1995;8:762–7.
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pulmonary edema. Pulm Med 2011;36193:1–7.
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